Figure 7.

Reduction of Hep G2 tumor burden by β-catenin Dicer-substrate short-interfering RNA (DsiRNA) treatment. Intravenous administration of β-cat-253-M14/M35 or the control DsiRNA HPRT1-716-M21/M36 to HPRT1 in LNP2072 (5 mg/kg three times a week × 2 weeks, seven doses total) began ~2 weeks after Hep G2 cells were implanted. Forty-eight hours after the last dose, animals were killed, and tumors were weighed. Means ± SEM are shown; statistics were calculated using one-way ANOVA and Bonferroni posttest analysis. β-cat-253-M14/M35, but not an HPRT1 DsiRNA, significantly reduced Hep G2 tumor weight.